OUR
PIPELINE

OUR
PIPELINE

Takeda Oncology is working to discover and develop innovative new therapies that will make a difference in patients' lives.

The molecules in our development pipeline are ordered by their phase in the clinical development process, and within each phase molecules are ordered alphabetically. Phase 1 trials are conducted to determine proper dosing, while Phase 2 and 3 Studies determine the efficacy, side effects and safety of the therapies being researched.

Certain molecules may be under study for more than one disease area. Click on the arrows to learn more about each one.

PROGRAMPhase Phase 11 Phase 22 Phase 33

BRIGATINIB

 
Anaplastic Lymphoma Kinase Inhibitor

Non-small Cell Lung Cancer

IXAZOMIB

 
Proteasome Inhibitor

Newly Diagnosed Multiple Myeloma

PONATINIB1

 
BCR-ABL Inhibitor

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

PEVONEDISTAT

 
NEDD8-Activating Enzyme Inhibitor

Higher-Risk Myelodysplastic Syndromes,
Chronic Myelomonocytic Leukemia,
Low-Blast Acute Myelogenous Leukemia

MOBOCERTINIB (TAK-788)

 
EGFR/HER2 EXON 20 Inhibitor

Non-Small Cell Lung Cancer

RELUGOLIX(TAK-385)

 
GnRH Antagonist

Prostate Cancer

TAK-079

 
Anti-CD38 Monoclonal Antibody

Multiple Myeloma

TAK-007

 
CD19 CAR-NK

Relapsed/ Refractory B-Cell Malignancies 

TAK-1024

 
GPC3 CAR-T

Solid Tumors

TAK-573

 
CD38 Attenukine

Relapsed/ Refractory Multiple Myeloma 

TAK-6055

 
Oncolytic Virus

Solid Tumors

TAK-676

 
STING Agonist

Solid Tumors

TAK-9406

 
CD19-1XX CAR-T

Relapsed/ Refractory B-Cell Malignancies 

TAK-981

 
SUMO Activating Enzyme Inhibitor

Non-Hodgkin Lymphoma, Solid Tumors

TAK-252/SL-2792527

 
Agonist Redirected Checkpoint Fusion Protein PD1/OX40L

Solid Tumors

Last updated 2021-04
All programs have Global Development Rights unless otherwise noted.

  1. Takeda shares development rights with Incyte Corp. (Europe, Turkey and Israel) and Otsuka Pharm. (Asia Pacific territories).
  2. Japan and Asian countries. In partnership with Myovant Sciences, Inc.
  3. Under licensing agreement and in collaboration with MD Anderson Cancer Center.
  4. Partnership with Noile-Immune Biotech.
  5. In collaboration with Turnerstone Biologics.
  6. Partnership with Memorial Sloan Kettering.
  7. Takeda retains an option to develop TAK-252 / SL-279252 with Shattuck Labs.